Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix
This article was originally published in The Pink Sheet Daily
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
You may also be interested in...
Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.
FDA clears Idelvion, a long-acting recombinant albumin fusion protein, with potential to provide up to 14-day dosing; Biogen's Alprolix is dosed once weekly.
Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.